A parallel controlled study on the efficacy fety of pivastatin atorvastatin in patients undergoing percutaneous coronary intervention

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15007035

Enrollment

Unknown

Registered

2015-07-29

Start date

2015-08-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute coronary syndrome

Interventions

Pivastatin:pivastatin 4mg po. pernight

atrovastatin:atrovastatin 20mg po. pernight

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with acute coronary syndrome undergoing percutaneous coronary intervention who were admitted in the department of second hospital of hebei university were enrolled.

Exclusion criteria

Exclusion criteria: 1. transplant patients with vascular disease; 2. patients with severe liver kidney function damage (total bilirubin greater than 3 times theper limit of normal, serum creatinine mmol >265 / l); 3. the horse of fluvastatin, atorvastatin aspirin, clopidogrel heparin, stainless steel, contrast agent or sirolimus allergic patients; 4. acute chronic infections autoimmune diseases; 5. patients with malignant tumor; 6. pulmonary heart disease congenital heart disease patients.

Design outcomes

Primary

Measure	Time frame
cholesterol;triglyceride;LDL-C;HDL-C;	—

Secondary

Measure	Time frame
hs-CRP;WBC;platelet aggregation rate;HbA1C;	—

Countries

China

Contacts

Public ContactGu Xinshun

gunew369@163.com+86 13930139688

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026